Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This book examines genotoxic impurities and their impact on the pharmaceutical industry. Specific sections examine this from both a toxicological and analytical perspective. Within these sections, the book defines appropriate strategies to both assess and ultimately control genotoxic impurities, thus aiding the reader to develop effective control measures. An opening section covers the development of guidelines and the threshold of toxicological concern (TTC) and is followed by a section on safety aspects, including safety tests in vivo and vitro, and data interpretation. The second section…mehr
This book examines genotoxic impurities and their impact on the pharmaceutical industry. Specific sections examine this from both a toxicological and analytical perspective. Within these sections, the book defines appropriate strategies to both assess and ultimately control genotoxic impurities, thus aiding the reader to develop effective control measures. An opening section covers the development of guidelines and the threshold of toxicological concern (TTC) and is followed by a section on safety aspects, including safety tests in vivo and vitro, and data interpretation. The second section addresses the risk posed by genotoxic impurities from outside sources and from mutagens within DNA. In the final section, the book deals with the quality perspective of genotoxic impurities focused on two critical aspects, the first being the analysis and the second how to practically evaluate the impurities.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in D ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
ANDREW TEASDALE, PhD, is a senior QA executive with AstraZeneca and chairs the company's internal genotoxic impurities advisory group. With over fifteen years of experience in analytical chemistry and quality assurance, Dr. Teasdale has published a number of papers relating to GIs and has been a speaker on genotoxic impurities at a number of conferences. Dr. Teasdale has also led two expert groups working in the field of genotoxic impurities, including an analytical group in the UK and a Project Quality Research Institute (PQRI) working group, which focused on the critical area of sulfonate ester formation and control.
Inhaltsangabe
Foreword ix Preface xi Contributors xiii Part 1 Development of Genotoxic Impurities Guidelines and the Threshold of Toxicological Concern Concept Chapter 1 Historical Overview of the Development of Genotoxic Impurities Guidelines and TheirImpact 3 Ron Ogilvie and Andrew Teasdale Chapter 2 Development of the Threshold of Toxicological Concern Concept and Its Relationship toDuration of Exposure 27 Alessandro Brigo and Lutz Müller Part 2 Evaluation of Genotoxic Risk from a Preclinical Perspective Chapter 3 Genetic Toxicity Testing to Qualify Alerting Impurities 67 Mike O'Donovan Chapter 4 Use of Structure Activity Relationship (SAR) Evaluation as a Critical Tool in the Evaluation ofthe Genotoxic Potential of Impurities 97 Susanne Glowienke and Catrin Hasselgren Chapter 5 Compound-specific Risk Assessments for Genotoxic Impurities: Examples and Issues 121 Andrew Teasdale and Charles Humfrey Chapter 6 Human Genotoxic Metabolites: Identification and Risk Management 151 Krista Dobo, Don Walker, and Andrew Teasdale Part 3 Perspective on Risk Posed by Genotoxic Impurities Chapter 7 Genotoxic Thresholds 171 Gareth J.S. Jenkins, George E. Johnson, James M. Parry, and Shareen H. Doak Chapter 8 Genotoxic Impurities: A Risk in Perspective 193 Dave Elder and Jim Harvey Part 4 Assessment of Genotoxic Risk: Quality Perspective Chapter 9 Strategies for the Evaluation of Genotoxic Impurity Risk 221 Andrew Teasdale, Dave Elder, and Simon Fenner Chapter 10 Analysis of Genotoxic Impurities: Review of Approaches 249 Dave Elder Chapter 11 Development of a Strategy for Analysis of Genotoxic Impurities 281 Andrew Baker Chapter 12 Strategic Approaches to the Chromatographic Analysis of Genotoxic Impurities 305 Frank David, Karine Jacq, Gerd Vanhoenacker, and Pat Sandra Chapter 13 Analysis of Genotoxic Impurities by Nuclear Magnetic Resonance Spectroscopy 351 Andrew Phillips Chapter 14 Mechanism and Processing Parameters Affecting the Formation of Sulfonate Esters:Summary of the Product Quality Research Institute Studies 385 Andrew Teasdale Chapter 15 Aspects to Consider When Low-level Active Pharmaceutical Ingredient/Drug ProductDegradants Have the Potential for Genotoxicity 409 Alan P. McKeown and Andrew Teasdale Index 423
Foreword ix Preface xi Contributors xiii Part 1 Development of Genotoxic Impurities Guidelines and the Threshold of Toxicological Concern Concept Chapter 1 Historical Overview of the Development of Genotoxic Impurities Guidelines and TheirImpact 3 Ron Ogilvie and Andrew Teasdale Chapter 2 Development of the Threshold of Toxicological Concern Concept and Its Relationship toDuration of Exposure 27 Alessandro Brigo and Lutz Müller Part 2 Evaluation of Genotoxic Risk from a Preclinical Perspective Chapter 3 Genetic Toxicity Testing to Qualify Alerting Impurities 67 Mike O'Donovan Chapter 4 Use of Structure Activity Relationship (SAR) Evaluation as a Critical Tool in the Evaluation ofthe Genotoxic Potential of Impurities 97 Susanne Glowienke and Catrin Hasselgren Chapter 5 Compound-specific Risk Assessments for Genotoxic Impurities: Examples and Issues 121 Andrew Teasdale and Charles Humfrey Chapter 6 Human Genotoxic Metabolites: Identification and Risk Management 151 Krista Dobo, Don Walker, and Andrew Teasdale Part 3 Perspective on Risk Posed by Genotoxic Impurities Chapter 7 Genotoxic Thresholds 171 Gareth J.S. Jenkins, George E. Johnson, James M. Parry, and Shareen H. Doak Chapter 8 Genotoxic Impurities: A Risk in Perspective 193 Dave Elder and Jim Harvey Part 4 Assessment of Genotoxic Risk: Quality Perspective Chapter 9 Strategies for the Evaluation of Genotoxic Impurity Risk 221 Andrew Teasdale, Dave Elder, and Simon Fenner Chapter 10 Analysis of Genotoxic Impurities: Review of Approaches 249 Dave Elder Chapter 11 Development of a Strategy for Analysis of Genotoxic Impurities 281 Andrew Baker Chapter 12 Strategic Approaches to the Chromatographic Analysis of Genotoxic Impurities 305 Frank David, Karine Jacq, Gerd Vanhoenacker, and Pat Sandra Chapter 13 Analysis of Genotoxic Impurities by Nuclear Magnetic Resonance Spectroscopy 351 Andrew Phillips Chapter 14 Mechanism and Processing Parameters Affecting the Formation of Sulfonate Esters:Summary of the Product Quality Research Institute Studies 385 Andrew Teasdale Chapter 15 Aspects to Consider When Low-level Active Pharmaceutical Ingredient/Drug ProductDegradants Have the Potential for Genotoxicity 409 Alan P. McKeown and Andrew Teasdale Index 423
Rezensionen
"Overall, a valuable addition to a pharmaceutical scientists' library. The topics covered are relevant and of interest to various 'stake-holders' in the drug development arena, including chemists, analysts and programme managers. I can recommend it." -- Journal of Organic Process Research & Development, 2011
"The style throughout is easy to read and content readily digested, especially those chapters [on] chemical process development and early-phase API development ... From a more practical point of view, the contents are well set out, and indexing appeared appropriate. ... Overall, a valuable addition to a pharmaceutical scientist's library. The topics covered are relevant and of interest to various 'stake-holders' in the drug development arena, including chemists, analysts, and programme managers. I can recommend it." -- American Chemical Society, 2011
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826